BioSpace News Archive

Heron Therapeutics, Inc. (Nasdaq: HRTX) today announced that the company will host a conference call and live webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to report fourth quarter and full year 2022 financial results and discuss recent business highlights.

Optimind Pharma Corp. (CSE: OMND) (the “Company”) wishes to announce that pursuant to its stock option plan, it has granted stock options to its directors, officers and consultants on March 8, 2023 to purchase up to 5,900,000 common shares of the Company at an exercise price of $0.05 per common share

Zynex, Inc. (Nasdaq: ZYXI) today announced that the company will report fourth quarter and full-year 2022 financial results on Monday, March 13, 2023.

Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the closing of its previously announced private placement of 3,843,309 ordinary shares (or ordinary share equivalents).

Immix Biopharma, Inc., a biopharmaceutical company pioneering Tissue-Specific Therapeutics ™ targeting oncology and immuno-dysregulated diseases, confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank or Silvergate Bank.

A new study by researchers at Hospital for Special Surgery (HSS) in New York City shows that this procedure does not make flatfoot worse in people with asymptomatic flatfoot and may even improve the condition.

Rakovina Therapeutics Inc. announces that it may apply to the TSX Venture Exchange to extend the expiry date of 11,414,750 common share purchase warrants issued by the Company.

Tango Therapeutics, Inc. reported that it is aware of the current situation affecting Silicon Valley Bank, it is monitoring this situation closely and does not expect its exposure to SVB will require any change to its previously provided guidance that it has sufficient cash, cash equivalents and marketable securities to fund operations into 2025.

Diamyd Medical announced that Karin Rosén, M.D, Ph.D, San Francisco, will join the Board of Directors as an adjunct member, and be proposed for election to the Board at its next General Meeting of Shareholders.

Surglasses/Caduceus S from Taiwan Main Orthopaedic Biotechnology Co., Ltd. Achieves Landmark Success with Caduceus S AR Spine Navigation System for First Augmented Reality Surgery in the US using 2D C-Arm Imaging.